Skip to main content

Table 3 Estimates of hazard ratio with multivariate analysis in HER2+/ER– and core basal subtypes, stratified by CD8+ iTIL status

From: Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Variable Whole subgroup With CD8+ iTIL = 0 With CD8+ iTIL ≥ 1
  HR (95% CI) P HR (95% CI) P HR (95% CI) P
HER2+/ER–  
Age 1.13 0.573 1.09 0.741 1.12 0.784
≥50 vs. <50 (0.74 - 1.73)   (0.65 - 1.84)   (0.50 - 2.50)  
Grade 2.23 0.007 2.05 0.039 2.55 0.134
3 vs. (1 and 2) (1.24 - 4.01)   (1.04 - 4.07)   (0.75 - 8.65)  
Tumor size 1.67 0.026 1.43 0.198 2.53 0.025
>2 cm vs. ≤2 cm (1.06 - 2.61)   (1.83 - 2.48)   (1.13 - 5.67)  
Nodal status 1.95 0.008 1.20 0.588 3.87 0.002
Positive vs. negative (1.19 - 3.21)   (0.62 - 2.35)   (1.67 - 8.96)  
LVI 1.34 0.250 1.47 0.261 1.56 0.268
Positive vs. negative (0.82 - 2.19)   (0.75 - 2.85)   (0.71 - 3.40)  
FOXP3+ iTIL 0.71 0.104 0.84 0.528 0.48 0.047
≥2 vs. <2 (0.46 - 1.07)   (0.48 - 1.49)   (0.23 - 0.98)  
Core basal  
Age 1.01 0.957 0.77 0.301 1.53 0.245
≥50 vs. <50 (0.68 - 1.50)   (0.47 - 1.26)   (0.75 - 3.12)  
Grade 1.30 0.417 1.55 0.257 1.91 0.387
3 vs. (1 and 2) (0.69 - 2.44)   (0.73 - 3.28)   (0.44 - 8.22)  
Tumor size 1.62 0.020 2.81 <0.001 0.77 0.470
>2 cm vs. ≤2 cm (1.08 - 2.43)   (1.67 - 4.72)   (0.38 - 1.57)  
Nodal status 2.37 <0.001 2.95 <0.001 1.64 0.212
Positive vs. negative (1.53 - 3.66)   (1.68 - 5.17)   (0.75 - 3.56)  
LVI 1.37 0.159 0.86 0.604 3.60 0.003
Positive vs. negative (0.88 - 2.13)   (0.49 - 1.51)   (1.56 - 8.29)  
FOXP3+ iTIL 0.53 0.002 0.66 0.130 0.93 0.845
≥2 vs. <2 (0.36 - 0.79)   (0.39 - 1.13)   (0.43 - 2.00)  
  1. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor-2; iTIL, intratumoral tumor-infiltrating lymphocyte; LVI, lymphovascular invasion.